• Je něco špatně v tomto záznamu ?

Defining A Liquid Biopsy Profile of Circulating Tumor Cells and Oncosomes in Metastatic Colorectal Cancer for Clinical Utility

S. Narayan, G. Courcoubetis, J. Mason, A. Naghdloo, D. Kolenčík, SD. Patterson, P. Kuhn, SN. Shishido

. 2022 ; 14 (19) : . [pub] 20221006

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031601

Metastatic colorectal cancer (mCRC) is characterized by its extensive disease heterogeneity, suggesting that individualized analysis could be vital to improving patient outcomes. As a minimally invasive approach, the liquid biopsy has the potential to longitudinally monitor heterogeneous analytes. Current platforms primarily utilize enrichment-based approaches for epithelial-derived circulating tumor cells (CTC), but this subtype is infrequent in the peripheral blood (PB) of mCRC patients, leading to the liquid biopsy's relative disuse in this cancer type. In this study, we evaluated 18 PB samples from 10 mCRC patients using the unbiased high-definition single-cell assay (HDSCA). We first employed a rare-event (Landscape) immunofluorescence (IF) protocol, which captured a heterogenous CTC and oncosome population, the likes of which was not observed across 50 normal donor (ND) samples. Subsequent analysis was conducted using a colorectal-targeted IF protocol to assess the frequency of CDX2-expressing CTCs and oncosomes. A multi-assay clustering analysis isolated morphologically distinct subtypes across the two IF stains, demonstrating the value of applying an unbiased single-cell approach to multiple assays in tandem. Rare-event enumerations at a single timepoint and the variation of these events over time correlated with progression-free survival. This study supports the clinical utility of an unbiased approach to interrogating the liquid biopsy in mCRC, representing the heterogeneity within the CTC classification and warranting the further molecular characterization of the rare-event analytes with clinical promise.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031601
003      
CZ-PrNML
005      
20230127131232.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14194891 $2 doi
035    __
$a (PubMed)36230811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Narayan, Sachin $u Michelson Center for Convergent Bioscience, Convergent Science Institute in Cancer, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA $1 https://orcid.org/0000000207871349
245    10
$a Defining A Liquid Biopsy Profile of Circulating Tumor Cells and Oncosomes in Metastatic Colorectal Cancer for Clinical Utility / $c S. Narayan, G. Courcoubetis, J. Mason, A. Naghdloo, D. Kolenčík, SD. Patterson, P. Kuhn, SN. Shishido
520    9_
$a Metastatic colorectal cancer (mCRC) is characterized by its extensive disease heterogeneity, suggesting that individualized analysis could be vital to improving patient outcomes. As a minimally invasive approach, the liquid biopsy has the potential to longitudinally monitor heterogeneous analytes. Current platforms primarily utilize enrichment-based approaches for epithelial-derived circulating tumor cells (CTC), but this subtype is infrequent in the peripheral blood (PB) of mCRC patients, leading to the liquid biopsy's relative disuse in this cancer type. In this study, we evaluated 18 PB samples from 10 mCRC patients using the unbiased high-definition single-cell assay (HDSCA). We first employed a rare-event (Landscape) immunofluorescence (IF) protocol, which captured a heterogenous CTC and oncosome population, the likes of which was not observed across 50 normal donor (ND) samples. Subsequent analysis was conducted using a colorectal-targeted IF protocol to assess the frequency of CDX2-expressing CTCs and oncosomes. A multi-assay clustering analysis isolated morphologically distinct subtypes across the two IF stains, demonstrating the value of applying an unbiased single-cell approach to multiple assays in tandem. Rare-event enumerations at a single timepoint and the variation of these events over time correlated with progression-free survival. This study supports the clinical utility of an unbiased approach to interrogating the liquid biopsy in mCRC, representing the heterogeneity within the CTC classification and warranting the further molecular characterization of the rare-event analytes with clinical promise.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Courcoubetis, George $u Michelson Center for Convergent Bioscience, Convergent Science Institute in Cancer, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA $1 https://orcid.org/0000000186226251
700    1_
$a Mason, Jeremy $u Michelson Center for Convergent Bioscience, Convergent Science Institute in Cancer, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA $u Catherine & Joseph Aresty Department of Urology, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA $u Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA $1 https://orcid.org/0000000259335003
700    1_
$a Naghdloo, Amin $u Michelson Center for Convergent Bioscience, Convergent Science Institute in Cancer, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA
700    1_
$a Kolenčík, Drahomír $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 32300 Pilsen, Czech Republic
700    1_
$a Patterson, Scott D $u Gilead Sciences, Inc., Lakeside Drive, Foster City, CA 94404, USA
700    1_
$a Kuhn, Peter $u Michelson Center for Convergent Bioscience, Convergent Science Institute in Cancer, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA $u Catherine & Joseph Aresty Department of Urology, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA $u Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA $u Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA $u Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA 90089, USA $u Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA $1 https://orcid.org/0000000326294505
700    1_
$a Shishido, Stephanie N $u Michelson Center for Convergent Bioscience, Convergent Science Institute in Cancer, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA 90089, USA
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 19 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36230811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131224 $b ABA008
999    __
$a ok $b bmc $g 1889566 $s 1182934
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 14 $c 19 $e 20221006 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace